PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27544060-0	2016	Clinical Activity of Alectinib in Advanced RET-Rearranged Non-Small Cell Lung Cancer.	alectinib	21-30	ret proto-oncogene	Homo sapiens	43-46	
27544060-2	2016	Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro.	alectinib	0-9	ret proto-oncogene	Homo sapiens	94-97	
27544060-3	2016	The clinical activity of alectinib in patients with RET-rearranged NSCLC has not yet been reported.	alectinib	25-34	ret proto-oncogene	Homo sapiens	52-55	
27544060-4	2016	METHODS: We have described four patients with advanced RET-rearranged NSCLC who were treated with alectinib (600 mg twice daily [n = 3] or 900 mg twice daily [n = 1]) as part of single-patient compassionate use protocols or off-label use of the commercially available drug.	alectinib	98-107	ret proto-oncogene	Homo sapiens	55-58	
27544060-10	2016	A fourth patient who was RET TKI-naive had primary progression while receiving alectinib.	alectinib	79-88	ret proto-oncogene	Homo sapiens	25-28	
27544060-11	2016	CONCLUSIONS: Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors.	alectinib	13-22	ret proto-oncogene	Homo sapiens	93-96	
27544060-11	2016	CONCLUSIONS: Alectinib demonstrated preliminary antitumor activity in patients with advanced RET-rearranged NSCLC, most of whom had received prior RET inhibitors.	alectinib	13-22	ret proto-oncogene	Homo sapiens	147-150	
27544060-12	2016	Larger prospective studies with longer follow-up are needed to assess the efficacy of alectinib in RET-rearranged NSCLC and other RET-driven malignancies.	alectinib	86-95	ret proto-oncogene	Homo sapiens	99-102